Related Experiment Videos
Systematic review of randomised controlled trials: probiotics for functional constipation
Anna Chmielewska1, Hania Szajewska
1Department of Paediatrics, The Medical University of Warsaw, 01-184 Warsaw, Dzialdowska 1, Poland.
World Journal of Gastroenterology
|December 30, 2009
Summary
Probiotic supplements show promise for treating constipation in adults and children. Specific strains like Bifidobacterium lactis and Lactobacillus casei improved bowel movements and stool consistency, but further research is needed.
Area of Science:
- Gastroenterology
- Microbiology
- Clinical Nutrition
Background:
- Constipation is a common gastrointestinal disorder affecting both pediatric and adult populations.
- Probiotics, live microorganisms conferring a health benefit, are explored for managing constipation.
- Evidence on probiotic efficacy for constipation requires systematic evaluation.
Purpose of the Study:
- To systematically review and update the evidence on the efficacy and safety of probiotic supplementation for constipation treatment.
- To analyze randomized controlled trials (RCTs) in pediatric and adult populations.
Main Methods:
- A comprehensive literature search was conducted in MEDLINE, EMBASE, CINAHL, and Cochrane Library databases up to May 2009.
- Included studies were randomized controlled trials (RCTs) involving adults and children with constipation.
- Data from five RCTs with a total of 377 participants were analyzed.
Main Results:
- In adults, specific probiotics including Bifidobacterium lactis DN-173 010, Lactobacillus casei Shirota, and Escherichia coli Nissle 1917 demonstrated positive effects on defecation frequency and stool consistency.
- In children, Lactobacillus casei rhamnosus Lcr35 showed a beneficial effect on constipation symptoms.
- Lactobacillus rhamnosus GG did not show a significant benefit in the pediatric group studied.
Conclusions:
- Current evidence suggests certain probiotic strains may be beneficial for treating constipation in adults and children.
- However, the use of probiotics for constipation is considered investigational due to limited available data.
- Further research is warranted to establish definitive efficacy and safety guidelines for probiotic use in constipation management.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:22Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:21Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...